Calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income attributable to IQVIA Holdings Inc.1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | 38.65 | = | 227.03 | ÷ | 5.87 | 5.87 | = | 1,091 | ÷ | 185,722,621 | |
| Feb 16, 2022 | 45.78 | = | 232.18 | ÷ | 5.07 | 5.07 | = | 966 | ÷ | 190,485,264 | |
| Feb 12, 2021 | 132.09 | = | 192.66 | ÷ | 1.46 | 1.46 | = | 279 | ÷ | 191,281,286 | |
| Feb 18, 2020 | 166.58 | = | 165.42 | ÷ | 0.99 | 0.99 | = | 191 | ÷ | 192,339,093 | |
| Feb 19, 2019 | 107.95 | = | 141.49 | ÷ | 1.31 | 1.31 | = | 259 | ÷ | 197,599,861 | |
| Feb 16, 2018 | 16.18 | = | 101.72 | ÷ | 6.29 | 6.29 | = | 1,309 | ÷ | 208,251,468 | |
| Feb 16, 2017 | 157.56 | = | 76.87 | ÷ | 0.49 | 0.49 | = | 115 | ÷ | 235,719,111 | |
| Feb 11, 2016 | 18.19 | = | 59.00 | ÷ | 3.24 | 3.24 | = | 387 | ÷ | 119,384,993 | |
| Feb 12, 2015 | 22.06 | = | 63.25 | ÷ | 2.87 | 2.87 | = | 356 | ÷ | 124,315,113 | |
| Feb 13, 2014 | 29.91 | = | 52.20 | ÷ | 1.75 | 1.75 | = | 227 | ÷ | 129,842,707 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
The financial trajectory from 2014 to 2023 is characterized by a consistent appreciation in share price contrasted with significant volatility in earnings per share (EPS), leading to erratic fluctuations in the price-to-earnings (P/E) ratio.
- Share Price Appreciation
- A strong and sustained upward trend is evident in the share price, which rose from 52.20 US$ in 2014 to a peak of 232.18 US$ in 2022, before settling at 227.03 US$ in 2023. This represents a substantial increase in market valuation over the ten-year period.
- Earnings Per Share (EPS) Volatility
- EPS exhibited extreme instability, with notable contractions occurring in 2017 (0.49 US$), 2019 (1.31 US$), and 2020 (0.99 US$). These troughs are punctuated by sharp recoveries, most notably in 2018 (6.29 US$) and again in the 2022-2023 period, where EPS reached 5.07 US$ and 5.87 US$, respectively.
- P/E Ratio Dynamics
- The P/E ratio shows an inverse correlation with EPS fluctuations. Between 2014 and 2016, the ratio compressed from 29.91 to 18.19. However, severe spikes occurred during periods of depressed earnings, specifically in 2017 (157.56) and between 2019 and 2021, where the ratio peaked at 166.58 in 2020. These anomalies indicate periods where the market price remained high despite a collapse in trailing earnings.
- Valuation Normalization
- A trend toward valuation stabilization is observed in the final two years of the period. As EPS grew consistently to 5.87 US$ by 2023, the P/E ratio declined from its historical peaks to 45.78 in 2022 and 38.65 in 2023, suggesting a realignment between the share price and the company's fundamental earning power.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Comparison to Competitors
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | 38.65 | 22.62 | 19.56 | 23.97 | 25.65 | 50.08 | 22.68 | 22.97 | 19.21 | 7.58 | 19.68 | 30.55 | 23.02 |
| Feb 16, 2022 | 45.78 | 22.07 | 21.05 | 20.92 | 29.94 | 40.66 | 12.36 | 20.93 | 14.78 | 11.76 | 8.37 | 27.35 | 26.55 |
| Feb 12, 2021 | 132.09 | 40.17 | 18.82 | — | 44.49 | 31.95 | 641.48 | 28.92 | 26.72 | 19.62 | 15.09 | 27.89 | 20.18 |
| Feb 18, 2020 | 166.58 | 17.82 | 17.07 | 41.99 | 38.34 | 16.19 | 16.45 | 25.99 | 20.60 | 11.63 | 19.86 | 33.36 | 52.90 |
| Feb 19, 2019 | 107.95 | 20.60 | 14.01 | 16.81 | 29.77 | 39.13 | 15.26 | 23.74 | 33.46 | 21.58 | 18.17 | 35.19 | 22.59 |
| Feb 16, 2018 | 16.18 | 35.47 | 64.06 | 103.55 | 27.25 | — | 22.75 | 268.10 | 61.63 | 9.99 | 28.99 | 37.66 | 155.08 |
| Feb 16, 2017 | 157.56 | 16.54 | 16.03 | 20.56 | 23.02 | 32.39 | 6.83 | 20.08 | 46.14 | 28.10 | 42.64 | 30.45 | — |
| Feb 11, 2016 | 18.19 | 17.01 | 15.95 | 64.22 | 17.85 | 33.35 | 6.75 | 18.80 | 31.64 | 26.37 | 60.50 | 26.19 | — |
| Feb 12, 2015 | 22.06 | 55.08 | 22.96 | 49.80 | 23.69 | 33.06 | 12.85 | 17.15 | 13.94 | 23.03 | 118.44 | 27.26 | — |
| Feb 13, 2014 | 29.91 | 19.64 | 18.69 | 35.01 | 19.74 | 13.88 | 42.00 | 18.72 | 37.83 | 9.32 | 77.00 | 38.43 | — |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 15, 2023 | 38.65 | 20.23 |
| Feb 16, 2022 | 45.78 | 19.27 |
| Feb 12, 2021 | 132.09 | 34.89 |
| Feb 18, 2020 | 166.58 | 21.03 |
| Feb 19, 2019 | 107.95 | 22.89 |
| Feb 16, 2018 | 16.18 | 35.21 |
| Feb 16, 2017 | 157.56 | 20.62 |
| Feb 11, 2016 | 18.19 | 19.37 |
| Feb 12, 2015 | 22.06 | 21.40 |
| Feb 13, 2014 | 29.91 | 19.54 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
| IQVIA Holdings Inc. | Health Care | |
|---|---|---|
| Feb 15, 2023 | 38.65 | 351,256.81 |
| Feb 16, 2022 | 45.78 | 21.55 |
| Feb 12, 2021 | 132.09 | 32.22 |
| Feb 18, 2020 | 166.58 | 22.09 |
| Feb 19, 2019 | 107.95 | 24.32 |
| Feb 16, 2018 | 16.18 | 33.04 |
| Feb 16, 2017 | 157.56 | 21.90 |
| Feb 11, 2016 | 18.19 | 19.53 |
| Feb 12, 2015 | 22.06 | 21.38 |
| Feb 13, 2014 | 29.91 | 18.67 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).